Literature DB >> 32966806

Discovery of a Functional Covalent Ligand Targeting an Intrinsically Disordered Cysteine within MYC.

Lydia Boike1, Alexander G Cioffi1, Felix C Majewski1, Jennifer Co1, Nathaniel J Henning1, Michael D Jones2, Gang Liu2, Jeffrey M McKenna2, John A Tallarico2, Markus Schirle2, Daniel K Nomura3.   

Abstract

MYC is a major oncogenic transcriptional driver of most human cancers that has remained intractable to direct targeting because much of MYC is intrinsically disordered. Here, we have performed a cysteine-reactive covalent ligand screen to identify compounds that could disrupt the binding of MYC to its DNA consensus sequence in vitro and also impair MYC transcriptional activity in situ in cells. We have identified a covalent ligand, EN4, that targets cysteine 171 of MYC within a predicted intrinsically disordered region of the protein. We show that EN4 directly targets MYC in cells, reduces MYC and MAX thermal stability, inhibits MYC transcriptional activity, downregulates multiple MYC transcriptional targets, and impairs tumorigenesis. We also show initial structure-activity relationships of EN4 and identify compounds that show improved potency. Overall, we identify a unique ligandable site within an intrinsically disordered region of MYC that leads to inhibition of MYC transcriptional activity.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  MYC; activity-based protein profiling; chemoproteomics; covalent ligand; cysteine; intrinsically disordered; transcription factor; undruggable

Mesh:

Substances:

Year:  2020        PMID: 32966806      PMCID: PMC7854864          DOI: 10.1016/j.chembiol.2020.09.001

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   8.116


  34 in total

Review 1.  MYC: connecting selective transcriptional control to global RNA production.

Authors:  Theresia R Kress; Arianna Sabò; Bruno Amati
Journal:  Nat Rev Cancer       Date:  2015-09-18       Impact factor: 60.716

2.  Cell cycle: repurposing MYC and E2F in the absence of RB.

Authors:  Joana Osorio
Journal:  Nat Rev Mol Cell Biol       Date:  2015-08-12       Impact factor: 94.444

3.  ProLuCID: An improved SEQUEST-like algorithm with enhanced sensitivity and specificity.

Authors:  T Xu; S K Park; J D Venable; J A Wohlschlegel; J K Diedrich; D Cociorva; B Lu; L Liao; J Hewel; X Han; C C L Wong; B Fonslow; C Delahunty; Y Gao; H Shah; J R Yates
Journal:  J Proteomics       Date:  2015-07-11       Impact factor: 4.044

Review 4.  Cell cycle: on target with Myc.

Authors:  M Zörnig; G I Evan
Journal:  Curr Biol       Date:  1996-12-01       Impact factor: 10.834

5.  Myc-nick: a cytoplasmic cleavage product of Myc that promotes alpha-tubulin acetylation and cell differentiation.

Authors:  Maralice Conacci-Sorrell; Celine Ngouenet; Robert N Eisenman
Journal:  Cell       Date:  2010-08-06       Impact factor: 41.582

6.  MYC regulation of a "poor-prognosis" metastatic cancer cell state.

Authors:  Anita Wolfer; Ben S Wittner; Daniel Irimia; Richard J Flavin; Mathieu Lupien; Ruwanthi N Gunawardane; Clifford A Meyer; Eric S Lightcap; Pablo Tamayo; Jill P Mesirov; X Shirley Liu; Toshi Shioda; Mehmet Toner; Massimo Loda; Myles Brown; Joan S Brugge; Sridhar Ramaswamy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-04       Impact factor: 11.205

7.  Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications.

Authors:  Carl C Ward; Jordan I Kleinman; Scott M Brittain; Patrick S Lee; Clive Yik Sham Chung; Kenneth Kim; Yana Petri; Jason R Thomas; John A Tallarico; Jeffrey M McKenna; Markus Schirle; Daniel K Nomura
Journal:  ACS Chem Biol       Date:  2019-05-13       Impact factor: 5.100

8.  MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.

Authors:  Dai Horiuchi; Leonard Kusdra; Noelle E Huskey; Sanjay Chandriani; Marc E Lenburg; Ana Maria Gonzalez-Angulo; Katelyn J Creasman; Alexey V Bazarov; James W Smyth; Sarah E Davis; Paul Yaswen; Gordon B Mills; Laura J Esserman; Andrei Goga
Journal:  J Exp Med       Date:  2012-03-19       Impact factor: 14.307

Review 9.  Targeting oncogenic Myc as a strategy for cancer treatment.

Authors:  Hui Chen; Hudan Liu; Guoliang Qing
Journal:  Signal Transduct Target Ther       Date:  2018-02-23

10.  An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets.

Authors:  Karen I Zeller; Anil G Jegga; Bruce J Aronow; Kathryn A O'Donnell; Chi V Dang
Journal:  Genome Biol       Date:  2003-09-11       Impact factor: 13.583

View more
  18 in total

Review 1.  Advances in targeting 'undruggable' transcription factors with small molecules.

Authors:  Matthew J Henley; Angela N Koehler
Journal:  Nat Rev Drug Discov       Date:  2021-05-18       Impact factor: 84.694

Review 2.  The emerging role of mass spectrometry-based proteomics in drug discovery.

Authors:  Felix Meissner; Jennifer Geddes-McAlister; Matthias Mann; Marcus Bantscheff
Journal:  Nat Rev Drug Discov       Date:  2022-03-29       Impact factor: 112.288

3.  Deubiquitinase-targeting chimeras for targeted protein stabilization.

Authors:  Nathaniel J Henning; Lydia Boike; Jessica N Spradlin; Carl C Ward; Gang Liu; Erika Zhang; Bridget P Belcher; Scott M Brittain; Matthew J Hesse; Dustin Dovala; Lynn M McGregor; Rachel Valdez Misiolek; Lindsey W Plasschaert; David J Rowlands; Feng Wang; Andreas O Frank; Daniel Fuller; Abigail R Estes; Katelyn L Randal; Anoohya Panidapu; Jeffrey M McKenna; John A Tallarico; Markus Schirle; Daniel K Nomura
Journal:  Nat Chem Biol       Date:  2022-02-24       Impact factor: 16.174

4.  Discovery of a Covalent FEM1B Recruiter for Targeted Protein Degradation Applications.

Authors:  Nathaniel J Henning; Andrew G Manford; Jessica N Spradlin; Scott M Brittain; Erika Zhang; Jeffrey M McKenna; John A Tallarico; Markus Schirle; Michael Rape; Daniel K Nomura
Journal:  J Am Chem Soc       Date:  2022-01-07       Impact factor: 16.383

Review 5.  MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Authors:  Seyed Esmaeil Ahmadi; Samira Rahimi; Bahman Zarandi; Rouzbeh Chegeni; Majid Safa
Journal:  J Hematol Oncol       Date:  2021-08-09       Impact factor: 17.388

6.  Functionalized Scout Fragments for Site-Specific Covalent Ligand Discovery and Optimization.

Authors:  Vincent M Crowley; Marvin Thielert; Benjamin F Cravatt
Journal:  ACS Cent Sci       Date:  2021-04-05       Impact factor: 18.728

7.  Ligandability of E3 Ligases for Targeted Protein Degradation Applications.

Authors:  Bridget P Belcher; Carl C Ward; Daniel K Nomura
Journal:  Biochemistry       Date:  2021-09-02       Impact factor: 3.162

Review 8.  The MYC oncogene - the grand orchestrator of cancer growth and immune evasion.

Authors:  Renumathy Dhanasekaran; Anja Deutzmann; Wadie D Mahauad-Fernandez; Aida S Hansen; Arvin M Gouw; Dean W Felsher
Journal:  Nat Rev Clin Oncol       Date:  2021-09-10       Impact factor: 66.675

Review 9.  Targeting NRF2 to treat cancer.

Authors:  Jared Sivinski; Donna D Zhang; Eli Chapman
Journal:  Semin Cancer Biol       Date:  2021-06-05       Impact factor: 15.707

Review 10.  The long journey to bring a Myc inhibitor to the clinic.

Authors:  Jonathan R Whitfield; Laura Soucek
Journal:  J Cell Biol       Date:  2021-06-23       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.